联环药业：控股子公司药品艾司唑仑片通过一致性评价

Core Viewpoint - The announcement by Lianhuan Pharmaceutical regarding the approval of its subsidiary's drug, Estazolam tablets, signifies a strategic advancement in the company's product portfolio, particularly in the area of anxiety and sleep disorders treatment [1] Group 1: Company Developments - Lianhuan Pharmaceutical's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for Estazolam tablets [1] - The drug has passed the consistency evaluation of quality and efficacy for generic drugs, indicating its compliance with regulatory standards [1] Group 2: Product Information - Estazolam tablets are primarily used for treating anxiety and insomnia, and they also serve purposes in managing tension, fear, as well as for anticonvulsant and antiepileptic effects [1] - The drug is classified as a commonly used benzodiazepine sedative-hypnotic medication, highlighting its relevance in clinical practice [1]